These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 17098383)

  • 1. Animal models for predicting potency of oral sustained-release adhesive microspheres in humans.
    Nagahara N; Akiyama Y; Higaki K; Kimura T
    Int J Pharm; 2007 Feb; 331(1):46-53. PubMed ID: 17098383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of oral mucoadhesive microspheres in man on the basis of the pharmacokinetics of furosemide and riboflavin, compounds with limited gastrointestinal absorption sites.
    Akiyama Y; Nagahara N; Nara E; Kitano M; Iwasa S; Yamamoto I; Azuma J; Ogawa Y
    J Pharm Pharmacol; 1998 Feb; 50(2):159-66. PubMed ID: 9530983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and evaluation of a novel gastric mucoadhesive sustained-release acyclovir microsphere.
    Liu H; Pan W; Ke P; Dong Y; Ji L
    Drug Dev Ind Pharm; 2010 Sep; 36(9):1098-105. PubMed ID: 20545521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alginate microspheres of isoniazid for oral sustained drug delivery.
    Rastogi R; Sultana Y; Aqil M; Ali A; Kumar S; Chuttani K; Mishra AK
    Int J Pharm; 2007 Apr; 334(1-2):71-7. PubMed ID: 17113732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of gastroretentive microspheres and sustained-release preparations using theophylline pharmacokinetics.
    Miyazaki Y; Yakou S; Takayama K
    J Pharm Pharmacol; 2008 Jun; 60(6):693-8. PubMed ID: 18498704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and in-vivo evaluation of insulin-loaded chitosan phthalate microspheres for oral delivery.
    Ubaidulla U; Khar RK; Ahmed FJ; Panda AK
    J Pharm Pharmacol; 2007 Oct; 59(10):1345-51. PubMed ID: 17910808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a sustained-release recombinant human growth hormone formulation.
    Kwak HH; Shim WS; Choi MK; Son MK; Kim YJ; Yang HC; Kim TH; Lee GI; Kim BM; Kang SH; Shim CK
    J Control Release; 2009 Jul; 137(2):160-5. PubMed ID: 19332090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of furosemide-loaded alginate microspheres prepared by ionotropic external gelation technique.
    Das MK; Senapati PC
    Acta Pol Pharm; 2007; 64(3):253-62. PubMed ID: 17695149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and evaluation of novel solid nanodispersion system for oral delivery of poorly water-soluble drugs.
    Nkansah P; Antipas A; Lu Y; Varma M; Rotter C; Rago B; El-Kattan A; Taylor G; Rubio M; Litchfield J
    J Control Release; 2013 Jul; 169(1-2):150-61. PubMed ID: 23570985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of ascorbic acid enhancement of the bioavailability and diuretic effect of furosemide.
    Lee MG; Chiou WL
    Drug Metab Dispos; 1998 May; 26(5):401-7. PubMed ID: 9571221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and evaluation of oral bioadhesive controlled release formulations of miglitol, intended for prolonged inhibition of intestinal alpha-glucosidases and enhancement of plasma glucagon like peptide-1 levels.
    Deshpande MC; Venkateswarlu V; Babu RK; Trivedi RK
    Int J Pharm; 2009 Oct; 380(1-2):16-24. PubMed ID: 19563873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biopharmaceutic evaluation of furosemide as a potential candidate for a modified release peroral dosage form.
    Ritschel WA; Menon A; Sakr A
    Methods Find Exp Clin Pharmacol; 1991 Nov; 13(9):629-36. PubMed ID: 1787770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced absorption of oral furosemide by bile juice in rats.
    Kim EJ; Han KS; Lee MG
    Res Commun Mol Pathol Pharmacol; 1999; 104(1):107-10. PubMed ID: 10604283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of gastrointestinal drug absorption in cynomolgus monkeys.
    Takahashi M; Washio T; Suzuki N; Igeta K; Fujii Y; Hayashi M; Shirasaka Y; Yamashita S
    Mol Pharm; 2008; 5(2):340-8. PubMed ID: 18247527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a novel sustained release formulation of recombinant human growth hormone using sodium hyaluronate microparticles.
    Kim SJ; Hahn SK; Kim MJ; Kim DH; Lee YP
    J Control Release; 2005 May; 104(2):323-35. PubMed ID: 15907583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desorption of furosemide from charcoal in vitro and in man.
    Roivas L; Kivistö KT; Neuvonen PJ
    Int J Clin Pharmacol Ther; 1994 Jul; 32(7):365-9. PubMed ID: 7952799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microminipig: A suitable animal model to estimate oral absorption of sustained-release formulation in humans.
    Hamada T; Watanabe Y; Iida K; Sano N; Amano N
    Int J Pharm; 2020 Jun; 584():119457. PubMed ID: 32464228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. pH-sensitive and mucoadhesive thiolated Eudragit-coated chitosan microspheres.
    Quan JS; Jiang HL; Kim EM; Jeong HJ; Choi YJ; Guo DD; Yoo MK; Lee HG; Cho CS
    Int J Pharm; 2008 Jul; 359(1-2):205-10. PubMed ID: 18490120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of oral absorption of griseofulvin, a BCS class II drug, based on GITA model: utilization of a more suitable medium for in-vitro dissolution study.
    Fujioka Y; Kadono K; Fujie Y; Metsugi Y; Ogawara K; Higaki K; Kimura T
    J Control Release; 2007 Jun; 119(2):222-8. PubMed ID: 17442444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey.
    Nishimura T; Amano N; Kubo Y; Ono M; Kato Y; Fujita H; Kimura Y; Tsuji A
    Drug Metab Dispos; 2007 Aug; 35(8):1275-84. PubMed ID: 17470527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.